BC
CNTA

Boxer Capital’s Centessa Pharmaceuticals CNTA Stock Holding History

Boxer Capital’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-770,708
Closed -$4.99M – 57
2023
Q3 		$4.99M Sell
770,708
-480,429
-38% -$3.29M 0.27% 52
2023
Q2 		$7.75M Hold
1,251,137
– – 0.36% 51
2023
Q1 		$4.82M Hold
1,251,137
– – 0.24% 51
2022
Q4 		$38.8M Hold
1,251,137
– – 2.04% 17
2022
Q3 		$5.03M Hold
1,251,137
– – 0.28% 54
2022
Q2 		$6.09M Hold
1,251,137
– – 0.39% 48
2022
Q1 		$11.3M Hold
1,251,137
– – 0.58% 41
2021
Q4 		$14.1M Sell
1,251,137
-83,090
-6% -$1.12M 0.55% 40
2021
Q3 		$22.3M Buy
1,334,227
+430,000
+48% +$8.9M 0.78% 37
2021
Q2 		$20.1M Buy
+904,227
New +$21.3M 0.71% 43

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Boxer Capital's CNTA Position: Q4 2023 in Review

Boxer Capital sold out of Centessa Pharmaceuticals (CNTA) in Q4 2023, closing a stake of 770,708 shares — an estimated $4.99M sold.

Boxer Capital first reported a position in CNTA in Q2 2021 and held it in 10 quarters. The position peaked at $38.8M in Q4 2022. 58 funds tracked by Wall St. Rank hold CNTA as of Q4 2023.

  • Boxer Capital reported no remaining Centessa Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Boxer Capital sold 770,708 Centessa Pharmaceuticals shares in Q4 2023, an estimated $4.99M.
  • Boxer Capital first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 10 quarters.
  • Boxer Capital's Centessa Pharmaceuticals position peaked at $38.8M in Q4 2022.
  • 58 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q4 2023.

Based on Boxer Capital's 13F filing for Q4 2023, filed 14 Feb 2024.